A team of researchers from the University of Manchester and Manchester University NHS Foundation Trust has made a significant breakthrough in the diagnosis of uterine cancer. They have developed a simple test that uses cell samples from urine and vaginal fluid to detect the disease in women with post-menopausal bleeding. This test has been described as a "game-changer" in the healthcare of thousands of women, potentially sparing them from invasive and costly procedures.
According to the UK's National Health Service, approximately 10,200 women are diagnosed with uterine cancer every year in the UK, with a 12% increase in cases over the past decade. Currently, women with post-menopausal bleeding are referred for urgent examinations, including ultrasound scans, biopsies, and hysteroscopy. However, only 5-10% of these women actually have cancer. The new test aims to reduce the number of unnecessary procedures and provide reassurance to women who test negative.
The study, published in The Lancet journal, involved 1,864 women who were referred to hospitals with post-menopausal bleeding. The test was able to correctly identify 80% of cancer cases when using both urine and vaginal fluid samples. The test also showed a high level of accuracy, with a negative predictive value of 98.8%. This means that women who test negative can be reassured that they are unlikely to have cancer.
The test was also found to be effective in detecting high-risk tumors, with 95.8% accuracy, and 96.4% accuracy in detecting cases that had spread outside the uterus. Notably, the test was 100% effective in detecting cancer in women with darker skin tones. The researchers believe that this test could be a major step forward in the early detection of uterine cancer.
Dr. Emma Davidson, a consultant at the University of Manchester, said that the test could provide rapid reassurance to women with post-menopausal bleeding, reducing the psychological and financial burden on healthcare systems. The test is expected to be confirmed in routine practice pending further evaluation.
Uterine cancer symptoms, according to the UK's National Health Service, include post-menopausal bleeding, heavy or irregular periods, and changes in vaginal discharge. Other symptoms may include abdominal or pelvic pain, pain during sex, and changes in bowel or bladder habits. Early detection is crucial in treating the disease effectively.
The researchers hope that their test will become a standard tool in the diagnosis of uterine cancer, enabling healthcare professionals to quickly and accurately identify women at risk. The test's high level of accuracy and simplicity make it an attractive solution for widespread use.
Key points
- The test uses cell samples from urine and vaginal fluid to detect uterine cancer with 98% accuracy.
- The test could spare thousands of women from invasive and costly procedures.
- Uterine cancer symptoms include post-menopausal bleeding, heavy or irregular periods, and changes in vaginal discharge.
